ClinicalTrials.gg
Not yet recruitingNCT07163702EXACTUpdated Sep 9, 2025

Efficacy and Safety of Xinglou Chengqi Granule for Acute Ischemic Stroke

A Phase 2 interventional study of High-dose Xinglou Chengqi granules and Low-dose Xinglou Chengqi granules and placebo in Acute Ischemic Stroke, sponsored by Dongzhimen Hospital, Beijing. Not yet recruiting at 1 site in Canada. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-09-09.

Sponsored by Dongzhimen Hospital, Beijing · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Ischemic Stroke by Dongzhimen Hospital, Beijing — 6 open to participants now, 6 under way, none of them phase 3. Ischemic Stroke · Dongzhimen Hospital, Beijing.

Planned enrollment
10th of 10
60 · median 456
Started
2025
with 1 other
Phase 2
2 of 16
1 open now
Registered
16th of 16
by date

Among the 16 studies in Ischemic Stroke by Dongzhimen Hospital, Beijing, this one is the 10th largest by planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2025, is one of 2 in phase 2, and was the 16th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

6 of the 16 studies in Ischemic Stroke by Dongzhimen Hospital, Beijing are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Ischemic Stroke by Dongzhimen Hospital, Beijing, or all of them as a file.
02

Study summary

This is a Ⅱa clinical trial. The purpose of this study is to preliminarily explore the optimal dosage of Xinglou Chengqi Granules in the treatment of acute ischemic stroke and to evaluate the efficacy and safety of Xinglou Chengqi Granules for acute ischemic stroke.

03

Conditions studied

  • Acute Ischemic Stroke

Browse trials for

Keywords

  • acute ischemic stroke
  • Xinglou Chengqi granules
  • randomized controlled trial
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Inpatients diagnosed with acute ischemic stroke.
  2. Meet the criteria of TCM phlegm-heat and fu-organ excess syndrome.
  3. Acute ischemic stroke within 7 days after onset.
  4. 6 ≤ NIHSS \<20.
  5. Aged 18-70 years, male or female.
  6. The patient or representative has signed .

Exclusion criteria

Exclusion Criteria:

  1. Suspected secondary stroke caused by brain tumor, brain trauma, hemopathy, etc.
  2. NIHSS Ⅰa ≥2.
  3. Already dependent in activities of daily living before the present acute stroke (defined as modified Rankin Scare score ≥2 )
  4. Received or planned thrombolysis or endovascular therapy after onset.
  5. Known severe liver or kidney dysfunction ( or aspartate transaminase > 2.5 times the value, serum creatinine > 1.5 times the upper limit of normal value)
  6. With cancers or uncontrolled diabetes.
  7. The expected survival time is less than 3 months.
  8. Patients who have used other traditional Chinese medicine for treating acute ischemic stroke since stroke onset.
  9. Patients with severe mental disorders, dementia, or other comorbid diseases that may affect neurological function examination.
  10. With a history of alcohol or drug abuse or drug dependence.
  11. Those known to be allergic to the investigated drug or its components.
  12. Pregnancy, potential pregnancy, or breastfeeding.
  13. Currently participating in other clinical trials during the past 3 months.
  14. Those who are judged by researchers to have poor compliance or are not suitable for participating in this study for any other reason.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    High-dose group

    16 g of Xinglou Chengqi granules will be given to participants in the high-dose group.

    Drug: High-dose Xinglou Chengqi granules

  • Active comparator
    Low-dose group

    8 g of Xinglou Chengqi granules and 8 g of placebo will be given to participants in the low-dose group.

    Drug: Low-dose Xinglou Chengqi granules and placebo

Interventions

  • DrugHigh-dose Xinglou Chengqi granules

    Patients will receive orally high-dose Xinglou Chengqi granules, combined with guidelines-based standard care.

    Also known as: Guidelines-based standard care

  • DrugLow-dose Xinglou Chengqi granules and placebo

    Patients will receive orally low-dose Xinglou Chengqi granules, combined with guidelines-based standard care.

    Also known as: Guidelines-based standard care

06

What researchers measure

Primary outcomes

  1. The change of NIHSS score from baseline to day 14.

    The change of the National Institutes of Health stroke scale (NIHSS) score from baseline to day 14 will be analyzed between groups.

    Time frame: Baseline and Day 14.

Secondary outcomes

  1. The proportions of patients with mRS ≤ 2 or mRS ≤ 1.

    The proportions of patients with modified Rankin Scale (mRS) ≤ 2 or mRS ≤ 1 will be analyzed between groups.

    Time frame: Day 30, Day 60 and Day 90.

  2. The change of NIHSS score

    The change of NIHSS score will be analyzed at days 7, 30, 60, and 90.

    Time frame: Day 7, day 30, day 60, day 90.

  3. The proportion of patients with Barthel Index score ≥ 95 or ≥ 75.

    The proportion of patients with Barthel Index score ≥ 95 or ≥ 75 will be analyzed at days 7, 14, 30, 60, and 90.

    Time frame: day 7, day 14, day 30, day 60, day 90.

  4. The change of EQ-5D score.

    The change of EQ-5D score from baseline to days 7, 14, 30, 60, and 90 will be analyzed between groups.

    Time frame: day 7, day 14, day 30, day 60, day 90.

  5. The incidence of new cardiovascular events.

    The incidence of new cardiovascular events will be analyzed at day 7, 14, 30, 60, and 90.

    Time frame: day 7, day 14, day 30, day 60, day 90.

07

Study locations

1 site
  • Dongzhimen Hospital, Beijing University of Chinese Medicine
    Richmond, British Columbia V7E 6J1, Canada
    • Xinxing Lai, M.D. · Contactnew-star@163.com · +8615901111280
    • Ying Gao, M.D. · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2025; primary completion for Sep 2026, 11 months later.

Of 82 non-industry phase 2 interventional studies under Ischemic Stroke, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 40. This study's planned 11 months is below that.

Counting every sponsor, half of 123 studies reached it within 28 months; a quarter within 15 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2025
First posted
Sep 9, 2025
StartEst.
Oct 1, 2025
Primary completionEst.
Sep 30, 2026
CompletionEst.
Sep 30, 2026
Last update
Sep 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07163702
Lead sponsor
Dongzhimen Hospital, Beijing
Responsible party
Ying Gao (Professor, Dongzhimen Hospital, Beijing) — Principal investigator
First posted
Sep 9, 2025
Start date
Oct 1, 2025 (estimated)
Primary completion
Sep 30, 2026 (estimated)
Completion
Sep 30, 2026 (estimated)
Last update
Sep 9, 2025

Study contacts

Xinxing Lai, M.D.
Contact
new-star@163.com
+8615901111280

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion